GSK and Hengrui Pharma enter agreements to develop up to 12 innovative medicines across Respiratory, Immunology & Inflammation and Oncology | GSK
Includes license for potential best-in-class PDE3/4 inhibitor (HRS-9821) in clinical development for treatment of COPD
GSK and Hengrui enter agreements to develop up to 12 innovative drugs across respiratory, #immunology & #inflammation and #oncology
Includes license for potential best-in-class PDE3/4 inhibitor in clinical dev for COPD
$500 million upfront, up to $12 billion total deal
www.gsk.com/en-gb/media/...
28.07.2025 12:24 — 👍 0 🔁 0 💬 0 📌 0
Gate enters into a collab & license agreement w #Lilly to discover/develop molecular gate medicines > #smallmolecules that can eliminate disease-causing proteins modulating the secretory translocon
Undisclosed upfront & equity investment, total deal up to $856m
www.businesswire.com/news/home/20...
25.07.2025 18:53 — 👍 0 🔁 0 💬 0 📌 0
Roche axes Carmot obesity asset, 3 cancer drugs in R&D clear-out
Roche has axed one of the obesity assets from its $2.7 billion Carmot Therapeutics
Roche has axed one of the #obesity assets from its $2.7 billion Carmot buyout. The dropped candidate, CT-173, is a long-acting PYY analog in preclinical dev
Carmot’s former lead asset CT-388, a GLP-1/GIP agonist, is pending a go decision for Ph3 in obesity
www.fiercebiotech.com/biotech/roch...
24.07.2025 19:57 — 👍 0 🔁 0 💬 0 📌 0
Dispatch emerges with $216M and plans for a ‘universal’ solid tumor therapy
The startup is using elements of gene and cell therapy to create medicines that could be useful against an array of tough-to-treat solid tumors.
Dispatch Bio emerges to develop a sequential gene & cell therapy for solid tumors
1) Engineered virus targets cancer cells > exposes antigen 🔥
2) CAR-T seeks out the antigen
3) Cancer cells are killed > release viral particles + antigen > flag nearby tumor > ♻️
www.biopharmadive.com/news/disptac...
23.07.2025 16:46 — 👍 0 🔁 0 💬 0 📌 0
Leriglitazone Marketing Authorization Application submitted for treatment of cerebral adrenoleukodystrophy has been validated by European Medicines Agency
Very encouraging news from Minoryx, one of my former #biotech portfolio companies
Minoryx is one step closer to achieving approval for leriglitazone (NEZGLYAL) as the only pharmacological treatment for patients suffering from #cALD, a devastating #orphan disease
www.minoryx.com/media/lerigl...
23.07.2025 14:30 — 👍 0 🔁 0 💬 0 📌 0
This is a great example of the kind of revenue generating assets that #pharma companies facing major #patent cliffs will need in the coming years
09.07.2025 13:02 — 👍 2 🔁 1 💬 0 📌 0
Regeneron $REGN in-licenses HS-20094, a clinical-stage dual GLP-1/GIP receptor agonist, from Hansoh Pharma. A Ph3 in #obesity in China and Ph2b trial in #diabetes are ongoing
$80 million upfront, with potential additional payments of up to $1.93 billion
investor.regeneron.com/news-release...
02.06.2025 12:23 — 👍 0 🔁 0 💬 0 📌 0
BioNTech partners with BMS to co-develop & co-commercialize BNT327, a PD-L1 x VEGF-A bispecific #antibody, for multiple solid tumors. $1.5 billion upfront, in a deal that could potentially exceed $11 billion
#oncology #deal #pharma
investors.biontech.de/news-release...
02.06.2025 11:54 — 👍 0 🔁 0 💬 1 📌 0
Pfizer Enters into Exclusive Licensing Agreement with 3SBio | Pfizer
Pfizer Inc. (NYSE: PFE) today announced it has entered into an exclusive global, ex-China, licensing agreement with 3SBio, Inc. (01530.HK), a leading Chinese biopharmaceutical company, for the develop...
Another China to West #oncology deal! Pfizer has entered into an exclusive global, ex-China, licensing deal with 3SBio for SSGJ-707, a bispecific PD-1 x VEGF #antibody. Phase 3 to initiate in #China in 2025
$1.25 billion upfront and up to $4.8 billion in milestones
www.pfizer.com/news/press-r...
20.05.2025 06:26 — 👍 1 🔁 0 💬 0 📌 0
Excited to be attending the 25th #BioEquityEurope in Bruges! Looking forward to reconnecting with fellow investors and #biotech colleagues across the life sciences ecosystem.
Feel free to reach out if you'd like to connect during the event!
#venturecapital #lifesciences
12.05.2025 08:17 — 👍 2 🔁 0 💬 0 📌 0
ADAPTAM Therapeutics. The Next Era Of Cancer Immunotherapy.
Adaptam Therapeutics brings better therapies to oncology patients thanks to immunotherapies that target the immunosuppressive myeloid tumor.
We are excited to support Adaptam’s mission to pioneer a new era of cancer #immunotherapy!
Learn more about Adaptam at: www.adaptamtx.com
#portfolionews #venturecapital #biotech #lifesciences #oncology #cancer #tumor #macrophages #glycobiology #glycans
30.04.2025 11:30 — 👍 0 🔁 0 💬 0 📌 0
A spin-off from @cicbiogune.bsky.social, Adaptam has recently been awarded an @erc.europa.eu Proof of Concept grant to develop myeloid-targeted cancer therapies, making it the second #ERCPoC received, together with a previous ERC Starting grant #ERCStG
30.04.2025 11:28 — 👍 3 🔁 1 💬 1 📌 0
Co-created by us at Criteria Bio Ventures, Adaptam is advancing a pipeline of first-in-class, antibody-based programs (ADCs and bispecific antibodies) targeting these central glycobiology pathways involved in myeloid immunosuppression
30.04.2025 11:26 — 👍 0 🔁 0 💬 1 📌 0
Adaptam's discoveries in #cancer immunology, T cell and #myeloid cell biology have revealed previously unexplored cancer dependencies, demonstrating that specific #glycan interactions with immune cells are key drivers of myeloid-mediated immune suppression
30.04.2025 11:24 — 👍 0 🔁 0 💬 1 📌 0
The TME in solid tumors is enriched in immunosuppressive #myeloid cells, eg tumor-associated #macrophages (TAMs), which drive resistance or a lack of response to existing treatments. This remains one of the toughest challenges in cancer #immunotherapy
30.04.2025 11:23 — 👍 0 🔁 0 💬 1 📌 0
Happy to announce the launch of Adaptam Therapeutics, a new #biotech company pioneering #cancer immunotherapies by disrupting the immunosuppressive #myeloid TME through glyco-immune checkpoints to treat solid tumors
I’m proud to be a founding member and to have led its incubation as Board Director
30.04.2025 11:22 — 👍 3 🔁 0 💬 1 📌 0
Our mission is to accelerate the development of breakthrough immune therapies to turn all cancers into curable diseases.
Assistant professor at UCSF. Cell biologist at heart, research focus on the function and dynamic regulation of the nuclear periphery.
www.buchwalterlab.UCSF.edu.
PhD student at Netherlands Cancer Institute | Leila Akkari lab | macrophages in brain cancer
Accelerating and supporting high-impact cancer research at a major international funding initiative, for the benefit of cancer patients. Opinions exclusively my own.
Scientist at DKFZ and EMBL in Heidelberg, loving stats, genomics and genetics. @OliverStegle@genomic.social. For group news see @steglelab.bluesky.social
Computational oncologist at Memorial Sloan Kettering Cancer Center. Views and posts are my own and do not represent MSK.
Clasp Therapeutics aims to bring absolute precision to immuno-oncology by developing next-generation T cell engagers that target common oncogenic driver mutations across hard-to-treat cancers.
Chemical biology, CRISPR and beta-cell biology @ Broad Institute | Harvard Medical School | Brigham and Women's Hospital
Now mitochondria & metabolism @MSKCancerCenter, was biomaterials & tissue engineering @ColumbiaBME | 🇬🇹
Postdoctoral Junior Leader at CNIO funded by LaCaixa | Cancer genomics, evolution & early detection | Heptathlete forever
A translational research lab @mskcancercenter.bsky.social focused on the immunobiology and therapeutic potential of genetically engineered #Tcells and #TCRs. Est. 2016 @NYC
We use a technology-based approach to understand how our T cells recognize cancer. @nkinl.bsky.social | Tweets from lab members
Fascinated about non coding RNA and microproteins. Willing for clinical translation. Energy from family and friends. Believer in RNA biology and therapy. Living in CIMA, at University of Navarra.
🔬PhD student @icr.ac.uk studying phenotypic plasticity in paediatric cancer
⏪ Previously @stjuderesearch.bsky.social and @radboudumc.bsky.social
Junior Group Leader at the University of Oxford
Interested in brain cancer plasticity and therapy resistance
https://www.oncology.ox.ac.uk/team/lucy-brooks
www.brookslab.co.uk
PhD student at The Netherlands Cancer Institute | Leila Akkari lab | macrophages in brain cancer
Physician-scientist at MD Anderson Cancer Center investigating cellular immunotherapy for solid cancers with a focus on the solid TME. Opinions are my own.
Senior Research Scientist at Memorial Sloan Kettering Cancer Center
Cancer Biologist | Translational Research | Drug Discovery | Targeted Therapy | Biomarker Research
Senior Research Scientist at CZ Biohub New York, AI/ML Platform. Building causal AI models of immune cells.
Cancer immunotherapy, CAR T cells, TME, metastasis, spatiotemporal transcriptomics | PostDoc @Gladstone-USCF Institute of Genomic Immunology | MD, PhD at Technical University of Munich
